Bacteriophage Therapy Market

Market Outlook

The global bacteriophage therapy market, valued at USD 58.1 million in 2025, is projected to reach USD 66.5 million in 2026 and USD 266.8 million by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of target indication, urinary tract infections hold the highest (around 30%) share of the current market.
• With respect to route of administration, oral route dominates the current market.
• Based on the targeted bacteria, Escherichia coli captures the largest share (around 25) of the current bacteriophage therapy market.
• In terms of geographical regions, North America currently holds the highest market share (around 40).

Key Market Statistics

• Market Size in 2026: $66.5 Million
• Estimated Market Size in 2035: $266.8 Million
• CAGR (2026-2035): 16.7%
• North America: Largest market in 2026
• Asia-Pacific: Fastest growing region

Market Introduction

Antimicrobial resistance (AMR) has emerged as one of the greatest threats to public health, over the past few years. According to the Centers for Disease Control and Prevention, more than 2.8 million cases of AMR infections are identified in the United States on an annual basis, leading to death of more than 35,000 people. To address this situation, WHO has developed a global action plan for raising public awareness, reducing the incidence of infections, and optimizing the use of antimicrobial drugs. Moreover, the increasing urgency to overcome antibiotic resistance has consequently intensified the interest of researchers in developing alternative anti-infectious modalities.

One example of anti-infective modalities aimed at combating the escalating global burden of antimicrobial resistance (AMR) includes bacteriophage therapy, which has re-emerged as a promising precision medicine approach. Unlike broad-spectrum antibiotics, bacteriophages selectively infect and lyse pathogenic bacteria while preserving the host microbiome. Moreover, phage therapeutics tend to cause minimal genotoxicity, replicate at the site of action, produce fewer side-effects, and self-decompose, making them an attractive alternative for treating multidrug-resistant (MDR) infections.

Over time, the bacteriophage therapy domain has witnessed significant growth, transitioning from compassionate-use cases toward structured clinical development and regulatory engagement. The encouraging progress of clinical-stage candidates like Locus Biosciences' CRISPR-enhanced phage platform and Armata Pharmaceuticals' pathogen-specific phage therapies illustrate the industry's shift toward scalable, evidence-based products. These products are capable of addressing critical unmet needs in antimicrobial resistance.

Gradually, bacteriophage therapy is expected to evolve from an experimental intervention into an integral component of precision infectious disease management. Advances in phage engineering, artificial intelligence-enabled phage discovery, personalized phage cocktails, and combination therapies with antibiotics are expanding the therapeutic potential of this modality.

Top 10 Bacteriophage Therapy Companies

Market Segmentation

Based on the research, we have segmented the Bacteriophage Therapy Market into target indication, route of administration, targeted bacteria, and geographical regions.

By Target Indication

• Bacterial Dysentery
• Enteric Infections
• Gastrointestinal Infections
• Multiple Infections
• Prosthetic Joint Infection (PJI)
• Urinary Tract Infections

By Route of Administration

• Intravenous
• Oral
• Rectal
• Topical

By Targeted Bacteria

• Escherichia coli
• Pseudomonas aeruginosa
• Salmonella
• Staphylococcus aureus
• Streptococcus
• Others

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Bacteriophage Therapy Market Key Insights

What are the Key Drivers for Bacteriophage Therapeutics Growth?

• Rising Burden of Antimicrobial Resistance (AMR): The rapid increase in multidrug-resistant bacterial infections is a key factor driving the adoption of bacteriophage therapy. According to WHO estimates, antimicrobial resistance was directly associated with approximately 1.27 million deaths, while drug-resistant infections could contribute to more than 39 million deaths by 2050 if left unchecked. As a result, bacteriophages are being increasingly investigated as a next-generation alternative to conventional antibiotics because they can selectively target pathogenic bacteria while preserving beneficial microbiota.
• Advancements in Phage Engineering and Precision Medicine: Continuous innovations in synthetic biology, genomic sequencing, artificial intelligence (AI), and CRISPR technologies are significantly improving bacteriophage discovery, characterization, and therapeutic optimization. These technologies enable the development of highly targeted phage cocktails, engineered bacteriophages, and personalized treatment approaches with improved efficacy and reduced bacterial resistance. Companies like Locus Biosciences are developing CRISPR-enhanced phage therapies, while AI-driven phage screening platforms are accelerating candidate identification, thereby strengthening the commercial potential of bacteriophage therapeutics.

What are the Main Challenges for Market Growth?

• Lack of Harmonized Regulatory Frameworks Delaying Commercialization: Despite growing clinical interest, bacteriophage therapy continues to face regulatory uncertainty across major healthcare markets. Existing pharmaceutical approval pathways were primarily designed for conventional chemical drugs and are not fully suited for adaptive biological products, such as bacteriophages. Therefore, the absence of globally harmonized standards for manufacturing, quality control, and clinical evaluation often prolongs development timelines, increases compliance costs, and delays commercialization of novel phage therapeutics.
• Complex Manufacturing and Product Standardization: Manufacturing bacteriophage therapeutics at commercial scale presents significant technical challenges due to the biological variability of phages and the need for stringent purification and quality assurance processes. Ensuring batch-to-batch consistency, long-term stability, and regulatory-grade production remains difficult, particularly for personalized phage cocktails tailored to individual bacterial strains. These complexities increase production costs and limit large-scale manufacturing capabilities, posing a barrier to widespread market adoption.

Recent Developments

• In June 2026, Intralytix received a multimillion-dollar NIH Research Program Project (P01) grant as part of the University of Pittsburgh's initiative to accelerate phage therapy against ESKAPE pathogens.
• In May 2026, Armata Pharmaceuticals received FDA Fast Track designation for AP-SA02, supporting accelerated development of its Staphylococcus aureus bacteriophage cocktail.
• In January 2026, Locus Biosciences secured a USD 3.3 million contract (with the potential to reach $28 million) from the National Institute of Allergy and Infectious Diseases (NIAID) to support a proof-of-concept clinical trial of its AI-designed bacteriophage therapeutic LBP-PA01 for antibiotic-resistant Pseudomonas aeruginosa infections.

Industry Experts on Bacteriophage Therapy Market

Driven by the escalating prevalence of antibiotic-resistant bacterial infections, expanding clinical pipelines, and the growing demand for targeted alternatives to conventional antibiotics, the bacteriophage therapy domain is expected to grow in the near future.

Emphasizing on this, José Luis Bila (Chief Executive Officer at Precise Health), stated that, "So estimations from the World Health Organization and all the different surveillance programs we have estimate that there are 1.2 to 1.3 million deaths globally per year caused directly by antibiotic resistance. But there are actually around 5 million which are indirectly caused by antibiotic resistance"

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

• Chief Executive Officer, Small Company, France
• Senior Director, Head of Data-Science, Small Company, Israel
• Project Leader, Very Large Company, France
• Independent Consultant

In addition, the market report includes transcripts of the following other third-party discussions:

• Founder and Chief Executive Officer, Small Company, Greece
• Co-Founder and Chief Executive Officer, Small Company, Switzerland
• Chief Financial Officer, Mid-sized Company, US
• Chief Scientific Officer, Small Company, US
• Co-Founder, Small Company, US
• Staff Scientist & Principal Investigator, Very Large Company, US
• Production Specialist, Small Company, Portugal
• Professor of Medicine, Very Large Company, US
• Independent Researcher
• Independent Researcher

Market Share Insights

Which Target Indication Accounts for the Largest Share in the Bacteriophage Therapy Market?

This segment highlights the distribution of market value for bacteriophage therapy across various target indications, such as bacterial dysentery, enteric infections, gastrointestinal infections, multiple infections, prosthetic joint infection (PJI) and urinary tract infections.

Currently, the urinary tract infections segment captures the majority (around 30%) of the bacteriophage therapy market share. This dominance stems from the high global prevalence of recurrent and multidrug-resistant UTIs, particularly those caused by Escherichia coli, coupled with the growing clinical evidence that supports bacteriophage therapy as an adjunct or alternative to antibiotics. In addition, UTIs offer a relatively accessible treatment site, enabling localized phage delivery through intravesical or oral administration, while well-characterized bacterial pathogens facilitate the development of targeted phage cocktails. Increasing compassionate-use cases, particularly for recurrent MDR and ESBL-associated UTI treatment through customized or expanded-access phage approaches, and ongoing clinical studies have further strengthened the translational readiness of phage therapy for this indication.

In contrast, prosthetic joint infection (PJI) is expected to register the highest CAGR during the forecast period. This accelerated growth is driven by the increasing volume of orthopedic implant procedures worldwide and the rising incidence of biofilm-associated infections that remain difficult to eradicate using conventional antibiotics. As bacteriophages possess the unique ability to penetrate and disrupt bacterial biofilms, they are emerging as a promising adjunct to surgical debridement and antibiotic therapy. Growing clinical interest in personalized phage therapy, combined with expanding research collaborations and regulatory support for difficult-to-treat orthopedic infections, is expected to accelerate product development and commercial adoption in this high-value indication.

Market Share by Route of Administration: Oral Segment to Hold the Highest Market Share

Based on the route of administration, the global market is segmented into intravenous, oral, rectal, and topical routes.

Currently, the oral route is likely to capture the majority of the bacteriophage therapy market size. This is driven by the strong clinical focus on gastrointestinal and systemic bacterial infections, where oral formulations provide a non-invasive, patient-friendly, and scalable mode of administration. Advances in enteric-coated and microencapsulated phage formulations have significantly improved phage survival through the acidic gastric environment, enabling targeted delivery to the intestine while supporting outpatient treatment and long-term therapy. Additionally, the relative ease of manufacturing, distribution, and patient compliance associated with oral dosage forms makes this route particularly attractive for commercial-scale deployment.

Moreover, it is worth highlighting that, as per the bacteriophage therapy market analysis, the market share for topical sub-segment is likely to grow at a relatively higher CAGR during the forecast period. This growth is fueled by the increasing prevalence of chronic wound infections, diabetic foot ulcers, burn wounds, and surgical site infections, where localized phage delivery enables high therapeutic concentrations directly at the infection site with minimal systemic exposure. For instance, a randomized, double-blind Phase I / IIa study of TP-102 (a topical bacteriophage cocktail), evaluating the safety and tolerability in patients with infected and non-infected diabetic foot ulcers caused by pathogens like Staphylococcus aureus, validates this growing inclination towards topical administration of phage therapies.

Furthermore, topical administration bypasses physiological barriers that can reduce phage viability, allowing developers to demonstrate efficacy with lower doses and simplified formulation strategies.

Which Targeted Bacteria Holds the Largest Share in the Market?

Based on the targeted bacteria, the global market is segmented into Escherichia coli, Pseudomonas aeruginosa, Salmonella, Staphylococcus aureus, Streptococcus, and others.

According to our market analysis, Escherichia coli occupies the highest (around 25%) market share in the bacteriophage therapy market. This is primarily due to the significant global burden of E. coli-associated infections and the comparatively advanced stage of phage research targeting this pathogen. The availability of well-characterized phage libraries, a stronger body of preclinical and clinical evidence, and ongoing efforts to address multidrug-resistant E. coli infections have accelerated therapeutic development and early commercialization. Furthermore, the widespread clinical relevance of E. coli across urinary tract, gastrointestinal, bloodstream, and healthcare-associated infections has encouraged sustained investment from biotechnology companies and research institutions, reinforcing the segment's market leadership.

Regional Analysis: Which Regions are Showing the Fastest Growth in Bacteriophage Therapy Industry?

North America Market: Securing the Highest Share

In terms of geographical regions, the global market is distributed across North America, Europe, Asia-Pacific, and Rest of the World.

According to our bacteriophage therapy forecast, North America is likely to capture the majority (around 40%) of the bacteriophage therapy market share in the current year, and this trend is unlikely to change. This is primarily due to the region's advanced clinical development ecosystem, strong funding environment, and the presence of specialized phage therapy companies. Within North America, the US emerged as a key hub for phage therapy innovation, supported by the presence of companies like Locus Biosciences, Adaptive Phage Therapeutics, and Armata Pharmaceuticals. These key companies in the phage therapeutics industry are developing candidates across high-value indications, including recurrent urinary tract infections and chronic pulmonary infections. For instance, Locus Biosciences is advancing LBP-EC01 for multidrug-resistant E. coli urinary tract infections, while Armata Pharmaceuticals is evaluating AP-PA02 for chronic Pseudomonas aeruginosa lung infections. In addition, government-backed funding, including support from agencies, such as BARDA and the US Department of Defense, has helped strengthen the clinical and translational infrastructure for phage-based therapies.

Asia-Pacific: An Emerging Growth Spot

The bacteriophage therapy market in Asia-Pacific is likely to grow at a high CAGR during the forecast period till 2035. This is primarily due to the region's rising antimicrobial resistance burden, increasing healthcare investment, expanding biotechnology capabilities, and growing government focus on infectious disease management. Countries such as India, China, Japan, South Korea and Australia are witnessing increasing interest in alternative anti-infective approaches, including bacteriophage therapy, as antibiotic resistance becomes a larger public health concern. For instance, VICPhage, a clinical collaboration between The Alfred and Monash University, is among Australia's earliest integrated phage therapy programs, providing full-spectrum services from phage selection and preparation through to clinical administration.

Scope of Bacteriophage Therapy Market Report

Frequently Asked Questions

Question 1: What are bacteriophages?

Answer: Bacteriophages are viruses that have the ability to infect and kill the bacteria without affecting human or animal cells.

Question 2: What is phage therapy?

Answer: Phage therapy refers to the use of bacteriophages as a therapeutic modality for several infectious diseases, mainly bacterial infections.

Question 3: How big is the bacteriophage therapy market?

Answer: The global market size for bacteriophage therapy is estimated to be worth $66.5 million in 2026.

Question 4: What is the projected bacteriophage therapy market growth?

Answer: The market is expected to grow at a compound annual growth rate (CAGR) of nearly 16.7% during 2026-2035.

Question 5: Which region holds the highest market share in the bacteriophage therapy industry?

Answer: Presently, North America captures around 40% of the overall industry.

Question 6: Who are the leading players in the bacteriophage therapy industry?

Answer: Adaptive Phage Therapeutics, ContraFect, Eliava BioPreparations, Micreos, NPO Microgen, Phagelux, and Pherecydes Pharma are the key players in the bacteriophage therapeutics market.